Investigative Treatment for Advanced Prostate Cancer Uses Targeted Approach

The investigative therapy targets a specific molecule that is generally only expressed on the prostate cancer cell, according to a recent interview.

New research presented at the American Society of Clinical Oncology 2021 annual meeting has found encouraging results with the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.

Researcher Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, said any kind of cancer therapy should be as targeted as possible in order to attack cancer cells while avoiding healthy cells. Therapy with 177Lu-PSMA-617 is very precise, Morris said, because it targets a specific molecule that is generally only expressed on the prostate cancer cell.

Related Content:

ASCO Annual MeetingOncologyHospitalProstate Cancer
First Oral Medication for Blood Thinning in Children Granted FDA Approval
Expert: Although Women Are the Majority of Pharmacy Graduates, the ‘Leadership Numbers Have Remained the Same for the Past 40 Years’
Longer-Term Data for Axicabtagene Ciloleucel in Relapsed/Refractory Follicular Lymphoma Show Substantial Survival Improvement Over Current Therapies